TuHURA Biosciences Reports Increased R&D Expenses to $4.9M in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025; Net Cash Outflows Rise to $10.9M for First Half of 2025
TuHURA Biosciences, Inc. (NASDAQ:HURA) has reported financial results for the second quarter ending June 30, 2025. The company recorded research and development expenses amounting to $4.9 million, a significant increase from the $2.8 million recorded in the same period in 2024. Net cash outflows from operating activities were reported at $10.9 million for the six months ending June 30, 2025, compared to $8.9 million for the same period in 2024. Additionally, TuHURA completed a $12.5 million equity financing transaction and received $3 million from warrant exercise proceeds. In terms of corporate developments, TuHURA has been included in the Russell 3000® and Russell 2000® Indexes as of June 27, 2025. Furthermore, the company completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody, now named "TBS-2025." Plans are underway to initiate a Phase 2 trial of TBS-2025 in combination with a menin inhibitor for the treatment of relapsed or refractory NPM1-mutated Acute Myeloid Leukemia $(AML.AU)$ in the second half of 2025. TuHURA has also initiated a Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® for advanced and metastatic Merkel cell carcinoma (MCC).
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-108909), on August 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.